Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients

Z. Skacel, M. Marel, B. Malinova, J. Prausova, K. Kosatova (Prague, Czech Republic)

Source: Annual Congress 2002 - Lung cancer: treatment
Session: Lung cancer: treatment
Session type: Thematic Poster Session
Number: 2929

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Z. Skacel, M. Marel, B. Malinova, J. Prausova, K. Kosatova (Prague, Czech Republic). Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients. Eur Respir J 2002; 20: Suppl. 38, 2929

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009


Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009


Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005

Early concurrent normo- and hyperfractionated chemoradiotherapy in limited small cell lung cancer (LSCLC): a nonrandomized comparison of 22 consecutive patients
Source: Eur Respir J 2001; 18: Suppl. 33, 394s
Year: 2001

Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011


The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 672s
Year: 2004

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005

Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002

Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003


Rates of treatment response and median survival in advanced non small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Retrospective assessment of non small cell lung cancer stage IIIA-IIIB, treated with neoadjuvant chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010


The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007


Treatment of limited disease-small cell lung cancer
Source: Eur Respir Mon; 2009: 44: 299–309
Year: 2009

The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003

Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008